INEX and Alnylam Announce Allowance of New U.S. Patent Covering Delivery of RNAi Therapeutics

New Patent Broadly Covers Delivery of RNAi Therapeutics with Cationic Liposomes

09-Mar-2007

Inex Pharmaceuticals Corporation and Alnylam Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office (USPTO) has allowed claims in a patent application that covers nucleic acid-lipid compositions, including cationic liposomes, a family of specialized lipid molecules. Cationic liposomes enable the delivery of oligonucleotides, including small interfering RNAs (siRNAs). The USPTO issued a "Notice of Allowance" for patent application 09/431,594, which is derived from the "Wheeler" patent series and includes a number of patents licensed exclusively to INEX through agreements with the University of British Columbia, and which Inex has exclusively licensed to Alnylam for RNAi therapeutics. Following a "Notice of Allowance," the companies would expect final issuance of the patent within six months.

Cationic liposomes have been used as formulations to achieve systemic delivery of RNAi therapeutics in animal models including non-human primates (Zimmermann et al. (2006) Nature 441, 111-114). The newly allowed Wheeler patent covers cationic liposome compositions that contain oligonucleotides, including double-stranded RNAs such as siRNAs. In addition to the newly allowed patent, INEX and Alnylam have exclusive access to additional issued patents for delivery of oligonucleotides with cationic liposomes, including certain issued patents in the Wheeler patent series (U.S. Patent Nos. 5,976,567 and 6,815,432) and "Semple" patent series (U.S. Patent No. 6,858,225).

Other news from the department research and development

Most read news

More news from our other portals

Last viewed contents

Alnylam Announces Close of Investment and Expanded Agreement Related to the Tekmira-Protiva Business Combination - Agreement Expands Alnylam's Access to Key Technologies and Intellectual Property for Systemic Delivery of RNAi Therapeutics

Catalent Biologics and Valerius Biopharma to Collaborate on Manufacture of Specialty Biosimilars

AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage

AaviGen raises 17 million € in second financing round to advance precision gene therapies for heart failure towards the clinical stage

4SC strengthens patent protection for its epigenetic cancer drug in China

ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

ViGeneron closes of series A financing to drive development of next generation gene therapy pipeline

Heptares enters a research and drug discovery collaboration with Juntendo University

Novasep and instrAction enter a worldwide strategic alliance for non-chiral chromatography

Kedrion and ProMetic Form Strategic Alliance to Develop Orphan Drugs from Plasma

Alnylam and PBL Sign Licence Agreement for Baulcombe & Hamilton RNAi patent

QIAGEN and ActiveSight Sign Co-Marketing Agreement Targeting Protein Crystallography

U.S. Development Partner Quest Diagnostics Completes Clinical Development of Septin9 Colorectal Cancer Blood Test

Global Pharmaceutical companies expect hard price competition in the rising Biosimilars segment - Bi-annual survey among more than 80 executives from globally active pharmaceutical companies based in 16 countries and spread over four continents